Blockchain Registration Transaction Record
TransCode’s TTX-MC138 Shows Durable Disease Stabilization in Phase 1a Trial
TransCode Therapeutics reports Phase 1a results for TTX-MC138 showing durable disease stabilization in advanced cancer patients, supporting Phase 2a advancement. Learn more about RNAZ.
This news matters because it brings hope to patients with advanced cancers that have limited treatment options. TTX-MC138 targets microRNA-10b, a biomarker of metastasis, offering a novel approach to stabilize disease and potentially improve outcomes. The safety profile and durable responses seen in the trial support progression to Phase 2a, bringing this therapy closer to clinical availability for those in need.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0xbe93891ce8124fcb648d58f8e2deadecbf6351c638037660e3a811bffb8adfbb |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | xenoadMT-e3d6d8caa830943c431e281aee8ff37b |